Ahed H. Kattaa, Amit R. Persad, Paul M. Harary, Rodas Asrat Kassu, Muhammad Izhar, Santosh Guru, Amirhossein Akhavan-Sigari, David Arnold Purger, Yusuke S. Hori, Louisa Ustrzynski, Sara Coleman Emrich, Armine T. Tayag, Xuejun Gu, Lei Wang, Erqi Liu Pollom, Scott Gerard Soltys, David J Park, Steven D. Chang
This study assesses the efficacy, safety, and outcomes of SRS in patients with thalamic metastases, focusing on local control, overall survival (OS), progression-free survival, neurological outcomes, and treatment response factors.
BACKGROUND AND OBJECTIVES: The thalamus, a neural processor and integrator for forebrain activities, is an uncommon site for metastatic lesions. Stereotactic radiosurgery (SRS) has become a noninvasive treatment for brain metastases. This study assesses the efficacy, safety, and outcomes of SRS in patients with thalamic metastases, focusing on local control, overall survival (OS), progression-free survival, neurological outcomes, and treatment response factors. METHODS: test. Survival outcomes were assessed using Kaplan-Meier analysis, and model performance was evaluated using receiver operating characteristic analysis. A literature review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines supplemented the analysis. RESULTS: = .042). Cumulative 6-, 9-, 12-, and 24-month local control rates were 100%, 90%, 82.5%, and 78%. OS rates were 78.7%, 70.8%, 68.2%, and 40.4%, respectively. CONCLUSION: Our results showed sufficient local control after treatment. SRS demonstrates efficacy and safety in managing thalamic metastases, with high local control rates over time, supporting its role as an effective treatment option.